Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background And Aims: Recent studies indicate that proactive therapeutic drug monitoring (TDM) can improve clinical outcomes in patients with inflammatory bowel disease (IBD) treated with infliximab. Repetitive infliximab trough level (IFX TL) measurements for proactive TDM may increase patient inconvenience and medical costs. Therefore, we aimed to determine the optimal interval for TDM during infliximab maintenance therapy in patients with IBD.
Methods: A prospective cohort study was performed on the patients with IBD who were in clinical remission on infliximab maintenance therapy and had IFX TL ≥ 3 μg/mL after one-time dose optimization. Infliximab TL were measured before each infliximab infusion to identify the pharmacokinetic (PK) relapse (two consecutive IFX TL < 3 μg/mL). Kaplan-Meier method was used to calculate the time to PK relapse.
Results: A total of 103 patients were enrolled and followed for a median of 18.5 months. PK relapse occurred in 19 patients (18.5%), with a higher rate of PK relapse in patients with IFX TL 3-5 μg/mL (16/60, 26.7%) compared to those with IFX TL ≥ 5 μg/mL (3/43, 7.0%). Kaplan-Meier survival time to maintain 95%, 90%, 85%, 80%, and 75% therapeutic IFX TL persistence rate without PK relapse was 4.1, 10.3, 13.3, 14.3, and 19.8 months, respectively. Log-rank test showed that therapeutic IFX TL persistence rates were significantly lower in patients with IFX TL 3-5 μg/mL group compared to those with IFX TL ≥ 5 μg/mL group (p = 0.010). Kaplan-Meier retention time to maintain 85% therapeutic IFX TL persistence rate without PK relapse was 10.3 months in IFX TL 3-5 μg/mL group and 20.2 months in IFX TL ≥ 5 μg/mL group, respectively.
Conclusions: Proactive TDM measuring with IFX TL annually may be helpful in maintaining therapeutic IFX TL ≥ 3 μg/mL in 85% of patients with IBD and clinical remission on infliximab maintenance therapy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12367858 | PMC |
| http://dx.doi.org/10.1007/s10620-025-09032-9 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A series of pediatric patients with inflammatory bowel disease switching from intravenous to subcutaneous infliximab maintenance therapy.
Clin Res Hepatol Gastroenterol
September 2025
Pediatric Hepato-Gastroenterology and Nutrition Unit, Hôpital Femme Mère Enfant de Lyon Hôpital Femme Mère Enfant, Hospices Civils de Lyon HCL, Bron, France; Centre International de Recherche en Infectiologie (CIRI), Univ Lyon, Institut national de la santé et de la recherche médical (Inserm),
Objective: Infliximab is approved for pediatric Crohn's disease (CD) and ulcerative colitis (UC), but is limited in children by its intravenous administration. We evaluated the effectiveness and safety of switching from intravenous to subcutaneous infliximab in pediatric patients with CD/UC.
Methods: Multicenter retrospective cohort study, from January to December 2022 in two pediatric centers, that included CD/UC patients in clinical remission and weighing ≥50 kg, treated with maintenance dose IV IFX.
Optimizing the switch from escalated intravenous to subcutaneous infliximab: a population pharmacokinetics-pharmacodynamics study.
J Crohns Colitis
August 2025
Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.
Background And Aims: It remains unclear if patients on escalated intravenous (IV) infliximab can switch to standard subcutaneous (SC) infliximab CT-P13 of 120 mg bi-weekly (Q2W) injections without losing therapeutic response. This study investigates the dose-exposure-response relationship during the IV-to-SC switching of infliximab in Crohn's disease (CD) and ulcerative colitis (UC).
Methods: Data were collected from healthy volunteers and patients with CD and UC in different Phase I studies.
A literature survey on follow-up definitions on the use of infliximab in Crohn's disease.
Therap Adv Gastroenterol
August 2025
Oral and Maxillofacial Radiology, Applied Oral Sciences and Community Dental Care, Faculty of Dentistry, The University of Hong Kong, 34 Hospital Road, Sai Ying Pun, Hong Kong, China.
Many clinical studies arbitrarily define follow-up durations as short-term, mid-term, or long-term, without standardized criteria. To examine existing research on the use of infliximab in Crohn's disease to understand how these terms are defined and applied, a literature survey was conducted. Relevant studies were identified by querying Web of Science and Scopus with predefined keywords, focusing on articles that mentioned "short-term," "mid-term," or "long-term" in their title, abstract, or author keywords.
View Article and Find Full Text PDFIntroduction: Dose escalation with biologics is common among patients with ulcerative colitis (UC). We investigated the dose escalation and associated incremental costs among patients treated with biologics for UC.
Methods: This study utilized the Merative™ MarketScan® database in the United States (US) to identify adults with at least two claims for UC and at least two refill/infusion claims for maintenance doses of biologics (including adalimumab, infliximab, ustekinumab, and vedolizumab) from January 1, 2015, through December 31, 2022.
This case report describes the novel use of infliximab as maintenance therapy for both Crohn disease and idiopathic retroperitoneal fibrosis in a patient with concurrent disease. A 34-year-old man with Crohn disease developed a pelvic mass and hydroureteronephrosis, leading to an idiopathic retroperitoneal fibrosis diagnosis. Given shared inflammatory pathways, he was treated with prednisone followed by infliximab.
View Article and Find Full Text PDF